The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies Maurizio LucchesiIacopo SardiClaudio Favre Review Article 24 October 2017 Pages: 1047 - 1053
Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea Muhammad MasabMuhammad Wasif Saif Review Article 19 October 2017 Pages: 1055 - 1062
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer Nobuaki MatsubaraHirofumi MukaiChristian Zurth Original Article Open access 11 August 2017 Pages: 1063 - 1072
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer Nobuaki MatsubaraHirofumi MukaiChristian Zurth Erratum 23 October 2017 Pages: 1073 - 1077
Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane Chunze LiBei WangSandhya Girish Original Article 11 October 2017 Pages: 1079 - 1090
A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin Lorenzo Di Cesare MannelliMario MarescaCarla Ghelardini Original Article 12 October 2017 Pages: 1091 - 1103
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer Naminatsu TakaharaYousuke NakaiKazuhiko Koike Original Article 16 October 2017 Pages: 1105 - 1112
Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS) Andrés RedondoSilvia BaguéJavier Martin-Broto Original Article Open access 16 October 2017 Pages: 1113 - 1131
A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study Yasushi SatoMasahiro HirakawaTetsuji Takayama Original Article 16 October 2017 Pages: 1133 - 1139
The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer Kevin M. KochE. Claire DeesLionel D. Lewis Original Article 02 November 2017 Pages: 1141 - 1146
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC) Shang-Chiung ChenMatts KagedalChunze Li Original Article 17 October 2017 Pages: 1147 - 1159
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer Heinz-Josef LenzPhilip PhilipMaurice Berkowitz Original Article 17 October 2017 Pages: 1161 - 1169
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization R. B. VerheijenL. E. SwartN. Steeghs Original Article Open access 19 October 2017 Pages: 1171 - 1178
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients Kaiyan ChenXiaoqing YuYun Fan Original Article 24 October 2017 Pages: 1179 - 1187
Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer Satoshi KobayashiMakoto UenoShinichi Ohkawa Original Article 25 October 2017 Pages: 1189 - 1196
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer Daisuke SakaiHyun Cheol ChungToshihiko Doi Original Article Open access 25 October 2017 Pages: 1197 - 1207
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study Martin van den BentHui K. GanDavid A. Reardon Original Article Open access 26 October 2017 Pages: 1209 - 1217
The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer Masatoshi NomuraHidekazu TakahashiTsunekazu Mizushima Original Article 26 October 2017 Pages: 1219 - 1226
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study Jan de JongPeter HellemansDaniele Ouellet Original Article 28 October 2017 Pages: 1227 - 1237
Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6) Kiyoshi YoshinoShoji KamiuraTadashi Kimura Original Article 28 October 2017 Pages: 1239 - 1247
Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers Nagdeep GiriLisa H. LamM. Naveed Shaik Original Article 30 October 2017 Pages: 1249 - 1260
Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification Casey L. McAteeNetta SchnellerEric S. Schafer Short Communication 19 October 2017 Pages: 1261 - 1264
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine Joseph CiccoliniBruno LacarelleGĂ©rard Milano Letter to the Editor 13 October 2017 Pages: 1265 - 1266